Imfinzi improved pCR in gastric and GEJ cancers
2 June 2023 Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial First global Phase III trial of immunotherapy and chemotherapy combination to demonstrate clinical benefit in this settingTrial will continue to assess event-free survival Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's Imfinzi (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel)